Clinical Guides
Substance Misuse and Substance Use Disorders
A practical India-adapted guide to identifying harmful drug use, managing immediate risk, and linking people to evidence-based treatment without stigma or unsafe detoxification.
MedNext Academy | 13 min read
Substance Misuse and Substance Use Disorders
A practical India-adapted guide to identifying harmful drug use, managing immediate risk, and linking people to evidence-based treatment without stigma or unsafe detoxification.
Summary
Substance misuse describes psychoactive drug use that creates harm or substantial risk, while a substance use disorder is a clinical syndrome involving impaired control, prioritisation of use, persistence despite consequences, and sometimes tolerance or withdrawal. The substance, route, dose, frequency, co-use and context all matter. Opioids, cannabis, sedatives, stimulants, hallucinogens, inhalants, tobacco and non-medical use of prescription medicines produce different intoxication, withdrawal and chronic-harm patterns. Polysubstance use is common, so a single label or positive urine result is never an adequate formulation.
Care begins by deciding whether the person has an emergency: respiratory depression, severe agitation, hyperthermia, chest pain, seizure, delirium, major trauma, suicidal intent, psychosis or dangerous withdrawal. Stabilisation takes priority over diagnostic detail. Once immediate danger is addressed, the clinician should establish what was taken, when and how; assess dependence, physical and psychiatric comorbidity, pregnancy, infection exposure, safeguarding and social needs; then agree goals that may include survival, reduced harm, stabilisation, maintenance treatment, abstinence or recovery.
Moral judgement worsens concealment and disengagement. Use neutral language, preserve confidentiality within legal limits, and explain testing and treatment choices. Detoxification is not synonymous with treatment and can increase overdose risk when opioid tolerance falls. Effective care usually combines medical management, psychosocial support, harm reduction, continuing review and practical help with housing, violence, family responsibilities or employment. This guide is educational and does not provide a self-detoxification regimen or replace local emergency and specialist protocols.
How Common Is It?
India's 2019 national survey on the magnitude of substance use documented use of alcohol, cannabis, opioids, sedatives, inhalants and other drug categories across a large household sample, while also using additional methods to reach some populations poorly represented in household surveys. Its estimates are category-specific and should not be collapsed into one prevalence figure for substance use disorder. Use is not the same as harmful use or dependence, and a national estimate cannot predict severity in an individual. Under-reporting, criminalisation, stigma, homelessness and institutional residence can all affect measurement.
The clinical burden is broader than prevalence. Drug-related harm includes overdose, injury, infections, cardiovascular and neurological events, malnutrition, pregnancy complications, impaired caregiving, violence exposure, debt, school or work disruption, arrest and premature death. Patterns also change with availability and adulteration. A clinic that sees mostly opioid dependence should not assume opioids are the only locally important substance; emergency departments, dermatology, respiratory medicine, psychiatry, obstetrics and infectious-disease services encounter different presentations.
Ask locally relevant questions without stereotyping by age, occupation, sex, income or community. Adolescents and women may face particular barriers to disclosure and treatment, while people who inject drugs may avoid services because they expect discrimination. The 2019 report provides an important Indian baseline, but it predates later market and service changes. Current local surveillance, toxicology alerts and service data should therefore supplement it. Population numbers guide planning; a person's symptoms, function, risks and treatment preferences guide clinical decisions.
Risk Factors
No single factor causes a substance use disorder. Vulnerability can arise from early initiation, repeated exposure, high-potency products, rapid-delivery routes, genetic susceptibility, impulsivity, trauma, chronic pain, untreated mental illness, social exclusion and easy availability. Family history changes probability but is not destiny. Poverty, unstable housing, occupational injury, discrimination and disrupted education may increase exposure or reduce access to safer care; wealth does not confer protection. Prescribed opioids, sedatives or stimulants can also become harmful, so an apparently legitimate source does not remove the need for review.
Progression risk is strongly shaped by the drug and route. Injection increases overdose and blood-borne infection risk; smoking or inhaling can produce respiratory injury; combining opioids with alcohol or sedatives magnifies respiratory depression. Stimulant binges may be followed by exhaustion, depression or psychosis. Abrupt cessation of some sedative drugs can provoke seizures or delirium. Reduced tolerance after detoxification, hospitalisation, imprisonment or abstinence makes return to a previously used opioid amount especially dangerous.
Relapse is better understood as a signal to reassess than as a moral failure. Common contributors include craving, untreated pain, insomnia, depression, cue exposure, family conflict, violence, medication interruption, loss of housing, peer networks and lack of continuing care. Protective factors include a collaborative plan, reliable follow-up, safer social support, treatment for comorbidity, access to evidence-based medication where indicated, and an overdose response plan. Risk assessment must include vulnerability to exploitation, unsafe sex, trafficking, caregiving failure and harm to dependent children as well as harm directly caused by the substance.
Diagnosis
Diagnosis is clinical and should identify both the substance-related syndrome and the immediate medical state. Separate current intoxication, withdrawal, harmful use and dependence-like features from remote use. Clarify whether symptoms began before, during or after exposure and whether they resolve with sustained abstinence. A toxicology result can support an account but may miss a drug, remain positive after impairment has ended, or detect prescribed treatment. current guidelines specifically advises that biological testing form part of a comprehensive assessment rather than serve as the sole diagnostic method.
History
Use a substance-by-substance timeline covering names, street or brand forms, quantity, frequency, route, last use, binges, tolerance, withdrawal, craving, loss of control, unsuccessful change attempts and consequences. Ask about alcohol, tobacco, prescribed and over-the-counter medicines rather than focusing only on illegal drugs. Record overdose, seizures, delirium, injection practices, shared equipment, sexual risk, injuries, pain, pregnancy possibility and previous treatments. Assess mood, psychosis, cognition, trauma, suicide, violence, capacity, safeguarding, housing, finances, work and dependants.
Examination
Begin with airway, breathing, circulation, temperature, oxygenation, glucose and consciousness when acutely unwell. Look for respiratory depression, pupil changes, agitation, diaphoresis, tremor, ataxia, chest signs, arrhythmia, injection injury, infection, trauma, dehydration and malnutrition. Perform mental-state and neurological examinations, documenting delirium and risk.
Investigations
Target testing to the presentation: glucose, ECG, blood count, electrolytes, renal and liver function, pregnancy testing, creatine kinase, cardiac markers or imaging may be appropriate. Offer consent-based HIV, hepatitis B and hepatitis C assessment when exposure risk exists. Interpret toxicology within its detection window and limitations; unexpected results may require confirmatory laboratory analysis.
Differential Diagnosis
Altered behaviour should not automatically be attributed to drugs. Hypoglycaemia, hypoxia, sepsis, head injury, stroke, epilepsy, encephalitis, endocrine disturbance, hepatic or renal failure, heat illness and medication toxicity can resemble intoxication or withdrawal. Fluctuating attention, disorientation, abnormal vital signs, focal neurology or an unexplained reduction in consciousness demands medical assessment. An unverified report of drug use must never close the differential when the physiology suggests another emergency.
Primary psychiatric disorders can precede, coexist with or be precipitated by substance exposure. Mania, psychotic depression, schizophrenia-spectrum illness, panic, PTSD, ADHD and personality-related crises may affect use and presentation. Establish the temporal relationship: symptoms that persist beyond the expected drug effect, recur without use, or are accompanied by a longer decline in function require psychiatric evaluation. Conversely, a known psychiatric diagnosis must not obscure overdose, withdrawal or an adverse drug interaction.
Different substances also mimic one another. Opioid toxicity may coexist with sedative ingestion; agitation may reflect stimulants, withdrawal, delirium or akathisia; vomiting and abdominal pain have toxicological and non-toxicological causes. Prescribed dependence, recreational use, performance-enhancing products and contaminated preparations require distinct histories. Breath, urine or blood tests answer limited questions and do not measure consent, capacity, severity or motivation. The safest formulation lists the likely syndrome, plausible co-exposures, dangerous alternatives and what evidence would change management.
Management
Treat emergencies first using local resuscitation and poison-management protocols. Support airway and ventilation, correct glucose and temperature disturbances, manage seizures, arrhythmia, trauma and severe agitation, and obtain toxicology or critical-care advice when needed. A specific antidote may be appropriate for a recognised toxidrome, but response does not eliminate co-ingestion or the need for observation. Do not induce vomiting or offer improvised home remedies. Severe withdrawal, delirium, psychosis, pregnancy, serious comorbidity or an unsafe environment may require supervised inpatient care.
After stabilisation, establish a respectful therapeutic relationship and agree achievable goals. current guidelines recommends explaining abstinence-oriented, maintenance-oriented and harm-reduction options and sustaining engagement across transfers. Brief motivational work can help a person explore ambivalence without confrontation. Depending on the substance and service, treatment may include specialist medication, contingency management, family or couples work, psychological treatment for comorbid disorders, peer support and rehabilitation. Do not promise that one counselling method or a short admission will cure a chronic relapsing problem.
Harm reduction is active treatment: discuss avoiding mixing depressants, using sterile injecting equipment, blood-borne-virus testing and vaccination, sexual safety, not using alone, recognition of overdose and access to locally authorised naloxone programmes. Plan continuing care after any detoxification because tolerance loss raises overdose risk. Address pain, sleep, depression, psychosis, nutrition, dental health, housing, violence and employment. Document who will prescribe, who will monitor, where the next appointment occurs and what the patient should do if medication, transport or safety arrangements fail.
Prescribing Information
Medication choices depend on the substance, diagnosis, current intoxication, withdrawal severity, comorbidity, pregnancy, interactions and local authorisation. This page deliberately gives no dosing schedule. Opioid agonist maintenance and supervised detoxification medicines require trained assessment, controlled-drug governance and reliable follow-up. current guidelines describes methadone or buprenorphine as first-line options for opioid detoxification in its UK setting, but Indian clinicians must use current national and state rules, approved product information, institutional protocols and specialist advice. Never copy a UK regimen into unsupervised Indian practice.
Before prescribing, confirm identity and recent exposure as far as possible, assess tolerance and polysubstance use, check sedation and respiratory status, review other medicines, and evaluate hepatic, renal, cardiac and pregnancy factors. Explain the treatment goal, expected effects, impairment risks, safe storage, missed-dose procedure and review plan. Diversion and accidental ingestion by children are safety concerns, not reasons to deny evidence-based care. A treatment medicine can itself cause harm when combined with alcohol, benzodiazepines or other depressants.
Withdrawal management is substance-specific. Abrupt cessation of dependent sedative use may be dangerous; opioid withdrawal is distressing and relapse after lost tolerance can be fatal; stimulant withdrawal may bring severe depression or suicidality. Antagonist treatment after opioid use requires confirmation of an appropriate opioid-free interval by a specialist because precipitated withdrawal can be severe. Prescribing must be linked to psychosocial and physical-health care. Sedation, slow breathing, cyanosis, collapse, severe confusion, seizure, chest pain, hyperthermia, rigidity or suicidal deterioration requires urgent assessment, not remote dose advice.
When to Refer
Call emergency services or transfer to an emergency department for respiratory depression, reduced consciousness, cyanosis, seizure, severe chest pain, arrhythmia, hyperthermia, major agitation, delirium, serious injury, suspected poisoning, pregnancy with acute toxicity, suicidal intent or an unsafe violent situation. People with suspected opioid overdose need observation and an escalation plan even after apparent response because the opioid may outlast an antidote. Severe alcohol or sedative withdrawal, although covered by separate condition-specific guidance, is also a medical emergency risk.
Refer promptly to specialist addiction and mental-health services for dependence, repeated overdose, failed lower-intensity care, opioid or sedative use disorder, complex polysubstance use, psychosis, significant mood disorder, pregnancy, chronic pain with escalating use, cognitive impairment, homelessness, safeguarding concerns or uncertainty about a prescribed-drug problem. current guidelines recommends greater medical and nursing support when comorbidity or complex detoxification makes community care unsafe. Specialist referral should not be used to postpone infection testing, contraception discussion, wound care or basic mental-health treatment.
Make referrals operational rather than aspirational. Confirm that the service accepts the patient, document urgency, provide transport and contact information, reconcile medicines and specify interim responsibility. If a district lacks a specialist programme, use the MoHFW MNS service framework to identify primary, district and referral roles while seeking the safest available expert input. A rejected referral or missed appointment should trigger active re-engagement and risk review, not discharge for non-compliance.
Red Flags
Respiratory rate reduction, falling oxygen saturation, snoring or gurgling breathing, pinpoint pupils with impaired consciousness, cyanosis and inability to rouse suggest opioid or mixed-depressant toxicity. Other emergency patterns include severe chest pain, marked hypertension, arrhythmia, hyperthermia, profuse sweating, extreme agitation, seizure, rigidity, collapse or sudden neurological deficit after stimulant or unknown-drug exposure. Always check glucose, trauma and co-ingestion. A person who appears merely asleep may be dying from ventilatory failure.
Psychiatric danger signs include suicidal planning, intense post-binge depression, command hallucinations, persecutory fear with defensive behaviour, severe insomnia with escalating psychosis, inability to care for basic needs and delirium. Abrupt fluctuations in attention or orientation are not a routine feature of uncomplicated dependence. Withdrawal accompanied by seizure, hallucinations, profound confusion or autonomic instability needs urgent supervised care. Injection-related fever, spreading cellulitis, severe limb pain, breathlessness or a new murmur can indicate life-threatening infection or vascular injury.
Social red flags are equally actionable: dependent children left without safe care, sexual exploitation, trafficking, violence, coercive control, homelessness, unsafe injecting premises, loss of treatment supply and recent release from custody or discharge after abstinence. These circumstances can multiply overdose risk. Ask directly about access to potent opioids, sedatives, weapons and a safe observer. If the person cannot maintain immediate safety, do not rely on a routine outpatient appointment or a verbal promise to stop using.
Indian Clinical Context
India's Ministry of Health and Family Welfare operational guideline places substance use disorders within integrated Mental, Neurological and Substance Use care and describes links between health and wellness centres, higher facilities and specialist services. Actual staffing, medicines and referral capacity vary by state and district, so verify the receiving service instead of implying universal availability. The 2019 national survey from the Ministry of Social Justice and Empowerment provides substance-specific planning data and documents substantial treatment need; it should not be used to label communities or predict an individual's diagnosis.
Legal status, policing and fear of disclosure can deter people from seeking help. Clinicians should explain confidentiality, documentation and any mandatory safeguarding limits in understandable language. Care must remain respectful irrespective of whether a substance is illegal. Family members often provide transport, money and supervision; involve them with the patient's agreement where possible, while assessing violence, coercion, privacy and the safety of children. Women, adolescents, LGBTQ+ people, migrants and people who inject drugs may need tailored, non-discriminatory access.
Treatment plans must match real medicine supply, laboratory access, travel, cost and follow-up. current guidelines guidance is a useful evidence comparator for psychosocial assessment and opioid detoxification but is not Indian law or a local formulary. Verify current Indian controlled-drug requirements and locally authorised harm-reduction services. Do not publish a nationwide helpline number, guaranteed free treatment promise or naloxone-access claim without a current official source. When resources are limited, document the gap and specify the safest feasible interim plan.
NMC Competency Mapping
Substance misuse crosses psychiatry, pharmacology, medicine, emergency care, community medicine, forensic medicine and AETCOM. Mapping should use the institution's current authorised NMC CBME ledger rather than a fabricated condition code. At the knowledge level, learners should distinguish intoxication, withdrawal, harmful use and dependence-like syndromes; describe opioid, stimulant, cannabis, sedative and inhalant patterns; understand tolerance, overdose and relapse risk; and recognise that toxicology supports but does not replace clinical assessment.
At Know How and Show How levels, the learner should obtain a non-judgemental substance history, assess airway and consciousness, identify a toxidrome, screen suicide and safeguarding risk, interpret a test within its limitations, and make a safe referral. They should explain harm reduction, infection screening and tolerance loss after abstinence without giving an unsafe self-detoxification schedule. Communication assessment should reward confidentiality, shared goal setting and person-first language.
Useful stations include an unconscious patient handover, a motivational conversation after a non-fatal overdose, a polysubstance medication reconciliation and an assessment of injection-related infection. Prescribing questions should test governance, interactions, monitoring and escalation rather than memorised unsupervised doses. Learners must demonstrate that stabilisation is followed by continuing treatment and that a relapse prompts reassessment. Exact competency numbers, legal procedures and local referral pathways should be verified by faculty before incorporation into examinations.
Key Exam Pearls for NEET PG
A substance use disorder is diagnosed from a pattern of impaired control, priority, persistence and harm, not from one positive toxicology test. In any altered patient, begin with airway, breathing, circulation, temperature, glucose and consciousness. Opioid toxicity classically threatens ventilation; stimulants may produce agitation, hyperthermia, chest pain, arrhythmia or seizure; sedative withdrawal can be dangerous. Polysubstance exposure makes textbook toxidromes incomplete, and apparent intoxication does not exclude head injury, sepsis or hypoglycaemia.
A high-yield assessment records substance, route, amount, frequency, last use, tolerance, withdrawal, overdose, co-use, medical and psychiatric illness, pregnancy, infection exposure, suicide risk, safeguarding and social supports. Urine testing has detection-window and specificity limitations. Treat the patient, not the screen. Persistent psychosis outside the expected exposure course suggests a primary or enduring psychiatric disorder but still requires a longitudinal formulation.
Detoxification alone is not rehabilitation. Loss of opioid tolerance after abstinence increases fatal overdose risk, so continuing care and an overdose plan are essential. Evidence-based management combines emergency care when required, medication for selected disorders under regulated supervision, psychosocial intervention, harm reduction and treatment of comorbidity. Do not prescribe from an educational summary. Respiratory depression, seizure, delirium, hyperthermia, arrhythmia, major chest pain, suicidal intent and dangerous withdrawal require urgent escalation.
Frequently Asked Questions
Can a urine drug screen diagnose a substance use disorder by itself?
No. A screen may detect selected substances or metabolites within particular time windows, but it may miss newer drugs, show prescribed exposure, remain positive after impairment has ended or produce a result requiring confirmation. Diagnosis depends on history, examination, pattern of control and harm, function and clinical course. Testing should answer a defined clinical question and be interpreted with consent, assay limitations and possible co-exposures in mind.
Why can opioid overdose risk rise after detoxification or a period of abstinence?
Tolerance falls when opioid use stops. If a person later returns to an amount previously tolerated, that amount may suppress breathing. The danger is particularly important after detoxification, hospital admission, incarceration or any involuntary interruption. Continuing treatment, an overdose-response plan, avoidance of sedative combinations and access to locally authorised emergency measures are therefore essential; completing withdrawal is not the end of care.
Should every person who uses a drug be told that abstinence is the only acceptable goal?
No. The clinician should explain realistic abstinence-oriented, maintenance-oriented and harm-reduction options and agree goals with the person, while being clear about immediate dangers. Some situations require urgent stopping of exposure under medical supervision, but confrontation and moral judgement often reduce disclosure. Goals can change over time, and preserving life, preventing infection, stabilising treatment and maintaining engagement are meaningful clinical outcomes.
When does withdrawal require hospital or specialist supervision?
Urgent supervised care is needed when there is seizure, delirium, severe confusion, marked autonomic instability, psychosis, suicidality, pregnancy, serious medical disease, complex polysubstance dependence or an unsafe home environment. The risk varies by substance and co-use, so an online page cannot provide a universal taper. A clinician must assess recent exposure, previous complicated withdrawal, vital signs, mental state, support and access to monitoring before choosing a setting.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic